CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer

SIMPLE SUMMARY: This study reported our most recent results for targeting triple-negative breast cancer (TNBC) with a low survival rate, using CR6-interacting factor 1–cyclin-dependent kinase 2 (CRIF1–CDK2) interface inhibitors, by inhibiting the resistance to taxol treatment. Presently, over 50% of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Xiaoye, Belmessabih, Nassira, Wang, Ruixuan, Stephen, Preyesh, Lin, Sheng-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870401/
https://www.ncbi.nlm.nih.gov/pubmed/35205737
http://dx.doi.org/10.3390/cancers14040989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870401/
https://www.ncbi.nlm.nih.gov/pubmed/35205737
http://dx.doi.org/10.3390/cancers14040989

Ejemplares similares